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ABSTRACT 
Malaria remains the most deadly disease in the world with nearly 627 000 deaths and more 
than 200  million new clinical cases every year, the large majority occurring in sub Saharan 
Africa children aged < 5 years. This represents anyway a significant decrease as compared 
with the situation in the start of the Millennium.  This is due in part to the worldwide 
adoption of artemisinin-based combination therapy (ACT). However these gains are being 
threatened. A pattern of progressive decreased susceptibility of the parasite to the ACT key 
drugs, the artemisinin derivatives is emerging. Another central drug is quinine, still the 
mainstay for the treatment of severe malaria in Africa.  
The aim of this thesis was to contribute to the understanding of the genetic determinants of 
Plasmodium falciparum resistance to two key short half-life antimalarials, quinine and 
artesunate and to assess the parasite susceptibility to these drugs in Mali.  
In a clinical study on the efficacy of quinine 100% of severe Plasmodium falciparum infected 
patients were cured. For the first time, the pfnhe1 microsatellite allele ms4760-1, previously 
proposed to be involved with parasite in vitro resistance to this drug was selected post 
treatment pointing for this marker as also involved in the in vivo sensitivity of the parasite 
to quinine. Conversely, the ms4760 status of the initial infections was not predictive of the 
clinical outcome, leading to the conclusion that the ms4760-1 is likely a secondary factor of 
quinine resistance. The pfcrt K76T SNP was not shown to be under selection. In 
conclusion, albeit pfnhe1 has an undeniable contribution to the parasite response in vivo, 
other factors must be involved, supporting the view of quinine resistance as a complex 
multigenic trait. 
P. falciparum decreased sensitivity to artemisinin and its derivatives have been recently 
reported in SE Asia, including Thailand. We therefore performed an explorative study based 
on the determination of the in vitro sensitivity (IC50) of 47 culture adapted parasites from Mae 
Sot (Thai-Myanmar boarder) to a number of ACT drugs. These included artemisinin and 
dihydroartemisinin (DHA), the key metabolite of both artemether and artesunate.  The open 
reading frames of the drug transporter genes pfcrt, pfmdr1, pfmrp1 and pfmrp2 were further 
studied. Correlation analyses revealed two novel candidate markers of multidrug resistance: 
the pfmdr1 F1226Y and pfmrp1 F1390I SNPs, which were associated with 2-3 fold, increases 
in the IC50s of artemisinin and also the ACT partner drugs lumefantrine and mefloquine. 
 
An artesunate monotherapy (7 days) efficacy trial was performed at Malian malaria setting 
with the objective of detecting possible delayed P. falciparum clearance phenotypes, an 
early sign of decreased drug susceptibility. The microscopic based assessment of the 
infections did not reveal any extended parasitaemia clearance times with a median 
clearance time of 32 hours. Nevertheless there were clear inter-individual differences in the 
clearance dynamics. 
Recently, SNPs in the P.falciparum K13 propeller gene has been proposed to be markers of 
artemisinin resistance, i.e. of significantly increased clearance time in SE Asia. We 
therefore studied the polymorphisms in this gene in Mali and any possible association with 
the range of clearance times observed above. In addition, a set of samples from a previous 
cross section survey study, conducted prior to ACTs implementation, were analyzed in 
order to try to detect temporal changes in the sequence of the K13 propeller gene. The SE 
Asian mutations associated with artemisinin resistance were not found in Mali in any of the 
periods. Nevertheless, the K13 gene was found to be polymorphic in Mali even before the 
wide use of ACTs. No association was however found between polymorphism and parasite 
clearance rate. Interestingly, the SNPs found in the early cross-sectional study were different 
from those found in the later study. Further, the later study revealed mutations present near 
one of the key a.a. positions linked with resistance in Asia. These patterns merit further 
investigations.  
Finally, a new qPCR based approach was used to revisit the artesunate monotherapy study. 
This had the aim of increasing the sensitivity of parasite detection, in order to obtain an 
improved phenotype of parasite clearance, and hence improved conditions to search for a 
correlation between the presence of K13 mutation and the trend of prolonged parasite 
clearance. 
No clear association could be found even though the qPCR approach was able to find 
evidence of parasites 72 hours after artesunate treatment in more than 46% of infections 
previously considered as cleared by microscopy. Intriguingly no mutations in the K13 
propeller gene were found among the parasites classified as fast clearers by this method 
(parasites cleared at 24 hours after treatment).  
The result of the clinical trials showed high in vivo efficacies for both artesunate and 
quinine. However, this situation can rapidly change, as demonstrated by the recent 
emergence of artemisinin resistance in Asia. Molecular monitoring of any possible evolution 
and selection of antimalarial drug tolerance/resistance associated polymorphisms of 
  
genes such as Pfnhe-1 or K13 propeller are critical for optimal drug policies and sustained 
efficacy 
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1 INTRODUCTION 
 
1.1 MALARIA 
Malaria is globally the largest vector borne disease with over 200 million new clinical cases 
happening in low and middle-income countries every year. Presently it has an associated 
annual death toll of above 600 000 lives, the large majority among children under the age of 
5 years and pregnant woman (130, 216). In parallel with this mortality rate, the disease 
imposes a significant morbidity in society, with economic costs in the poorest part of the 
world representing up to USD 30 billion lost in Gross Domestic Product per year (168) 
Management of malaria accounts for 40% of all public health spending in those countries 
where the disease is a cause, but also a consequence of poverty. 
 
1.2 THE PLASMODIUM PARASITE 
Malaria is caused by a single cell protozoan parasite of the genus Plasmodium comprising 
more than hundred species (105), Only 5 species infect Humans: Plasmodium ovale, 
Plasmodium malariae, plasmodium knowlesi, plasmodium vivax and Plasmodium 
falciparum. This latest represents the most virulent species, responsible for the severe form of 
malaria and its highest mortality. Due to its importance in the African Continent, as well as 
notorious capacity to develop resistance against antimalarial-based therapies, the present 
thesis is focused in P. falciparum malaria. 
 
1.3 PLASMODIUM LIFE CYCLE 
The full life cycle of the malaria parasite, allowing the disease transmission and its spreading, 
is based on the alternately infection of human and mosquito hosts illustrated in Fig. 1. It starts 
with the need of an infected fertilized female anopheles to obtain blood, necessary for its eggs 
maturation. Upon a blood meal it injects plasmodium sporozoites at the same time as 
anticoagulants from her salivary glands, into the derma. In order to avoid as much as possible 
the host immune system, the sporozoites rapidly reach the liver, invading hepatocytes. There 
it starts its first asexual reproduction, developing schizonte forms in which thousands of 
merozoites develop. This hepatic phase of malaria (sometimes referred as the “silent phase”) 
is asymptomatic and develops for 5 to 16 days, depending of the species, being 5-10 days for 
P. falciparum (133). In the case of P. vivax and P. ovale infections, a fraction of the parasites 
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enrolled in the hepatic stage develop a dormancy state, the hypnozoite. These forms are able 
to stay dormant for large periods of time. Their reactivation is associated with disease bursts 
(“relapsing fever”), months or even years after the first infection (126). Mature hepatic 
merozoites, are released after rupture of infected hepatocytes, reaching the blood stream 
where they rapidly invade red blood cells (RBCs), initiating a cyclic asexual reproduction of 
24 to 72 hours depending on species (ca. 48 hours for P. falciparum). With each schizont 
producing up to 30 merozoites, every cycle releases millions of merozoites, causing the 
clinical effects of the infection. The merozoites swiftly invade new RBCs, reinitiating the 
intra-erythrocytic cycle, and the destruction of an increasing number of erythrocytes. 
In parallel, and responding to still not clearly identified stimuli, a fraction of merozoites exits 
the asexual multiplication cycle through a process of sexual differentiation. This leads to the 
development of male and female gametocytes, ready to be sucked during a female anopheles 
blood meal. Once in the mosquito gut, male and female gametocytes mature becoming fully 
functional gametes, fuse, and form a diploid zygote. This develops towards an ookinete, 
which migrates into the mosquito midgut wall. There it undergoes intense asexual division 
giving rise to an oocyst full of several thousands of haploid unicellular infecting sporozoites. 
After one to two weeks the oocyst bursts, releasing a large number of mature sporozoites in 
the mosquito abdominal cavity. This mobile stage then migrates upstream and invades the 
mosquito salivary gland. The cycle of human infection closes (and re-starts) upon the 
mosquito next blood meal, by injecting the sporozoites present in its salivary glands into the 
human host bloodstream. 
 
1.4 THE MOSQUITO HOST 
From over 400 species in the Anopheles genus, only 30 to 40 of them transmit malaria in 
natural condition. The highest reproduction rate of anopheles is observed in tropical regions 
where the humidity and heat are optimal for the mosquito to live long enough to allow the 
parasite to complete its life cycle into the anopheles host (female anopheles have a life 
expectancy of approximately one month). The time required for the mosquito to be infective 
to a human is 10 to 21 days following its infecting blood meal. This timeline depends on the 
parasite species and the temperature. In Africa, An. Gambiae and An. Funestus are both 
strongly anthropophilic, making of them the most efficient malaria vectors worldwide. 
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Figure 1 - The malaria life cycle (http://www.mmv.org/malaria-medicines/parasite-lifecycle) 
 
1.5 THE HUMAN HOST – ASPECTS OF SUSCEPTIBILITY 
There is strong evidence that humans and the malaria parasites have been evolving together 
for a large period of time. This co-evolution is visible by the geographical distribution of 
specific population genetic characters.  
It is generally accepted that malaria has its origins in Africa, where some genetic disorders 
have been shown to be protective against the severe forms of malaria. This is mostly visible 
in specific hematologic characteristics. Hemoglobinopathies like the presence of hemoglobin 
C or S are known to limit the parasite development in malaria infected RBCs and have been 
associated to a protective potential during an acute malaria infection(3, 30, 102), Similarly, 
deficiencies in the pentose phosphate pathway enzyme Glucose-6-Phosphate Dehydrogenase 
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(G6PD), as well as Alpha Thalassemia are considered to provide a certain degree of 
protection against severe malaria (65, 113, 198). The significant presence of those anomalies 
in Africa, particularly in heterozygote forms, is likely to be the result of the selection pressure 
of the lethal P. falciparum malaria on the human populations, thus modeling some 
characteristics of their genomes throughout a long co-evolution in the African continent. 
Similarly, the almost absence of Duffy antibody on melanoderma RBCs make the African 
populations resistant to P. vivax infection, common in other regions, namely in Asia and 
Latin America. (125) 
 
1.6 MALARIA PREMUNITION 
Premunition is the immunity developed to the infection after repeated exposure. It protects 
the host against hyperparasitemia without clearing the infection (167). It is rapidly and 
progressively acquired, short-lived, and partially effective (127). Thus, if an individual 
departs from an endemic area for an extended period of time, he or she is likely to lose the 
built up premunition, become again susceptible to malaria (127). Antibody action contributes 
to premunition, although it is generally accepted that this phenomenon is probably much 
more complex than simple antibody and antigen response (4, 221).  
 
1.7 CLINICAL MALARIA 
By the clinical manifestation, malaria can be classified into the most common uncomplicated 
malaria and its severe, life-threatening, forms. 
Uncomplicated malaria 
Uncomplicated malaria is characterized by recurrent attacks showing stages of chilling, 
followed by fever and a sweating phase. Those phases are combined to a number of diffuse 
symptoms including tiredness, vomiting, abdominal and muscle pains and headache, in 
absence of clinical or laboratory indicator of severity, including vital organ dysfunction. 
Anemia states are also frequent. Uncomplicated malaria is more seen among adults in high 
transmission areas (220), an observation probably related with the aforementioned 
premonition status which is acquired with several successive malaria infections. Left 
untreated, the condition poses the risk of developing towards its complicated forms, 
associated to a severe picture of the disease and a potentially fatal prognosis for the patient.  
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Severe malaria  
Complicated cases of malaria also called severe malaria are typically observed in individuals 
with a low level of premunition, essentially children under year of 5, pregnant woman and 
non-immune adults travelling to malaria transmission areas (220). Major clinical 
manifestations related to severe malaria include prostration, coma, severe anemia, breathing 
difficulties and low blood sugar. The mentioned prostration and coma symptoms are strongly 
associated with the specific condition referred as cerebral malaria. This represents one of 
most deadly manifestation of severe malaria, being a particular characteristic of P. falciparum 
infections; this particular severity of P. falciparum malaria is due to the ability of this parasite 
to express adhesive variant protein on the surface of their host RBC (27, 28, 162). The 
resulting knobs-like structures mediate the interaction of infected RBC with receptors located 
at the venal and capillary endothelium, leading to its attachment and cytoadherence. P. 
falciparum infected RBCs are also able to adhere to uninfected ones forming conglomerates 
designated as “rosettes”. Cytoadherence and rosetting are both central to the pathogenesis of 
P. falciparum malaria, resulting in the clogging in vascular structures of vital organs, namely 
the brain (28, 190).  
 
1.8  MAJOR ANTIMALARIAL DRUGS 
We give in here a brief description of the presently used major antimalarials, with a special 
emphasis on the ones under focus in this thesis, artemisinin derivatives and quinine. 
1.8.1 Aminoquinoline structure drugs - Amodiaquine and piperaquine 
Amodiaquine (AQ) is an old drug, having been developed in the late 1940s. Its use was 
limited for decades by the acceptance and implementation of chloroquine (CQ) as the global 
standard of anti-malaria treatment, as well as by a number of reports of rare - but serious - 
neutropenia and liver toxicity related side effects observed with prophylactic regimens (68, 
78, 132). The use of AQ as a prophylaxis agent is associated with its metabolism, as  this 
drug is extensively bio-transformed towards a main active metabolite desethylamodiaquine 
(DEAQ), characterized by a very long half-life up to more than 20 days. AQ has been 
proposed to act in a similar fashion as CQ, i.e. by inhibiting the bio-polymerization or the 
glutathione dependent destruction of the heme group resulting from the parasite haemoglobin 
degradation process (72, 225). By dint of its safety, AQ was recovered in the XXI Century as 
an ACT partner for the treatment of uncomplicated malaria, nowadays available as a 
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Artesunate-AQ (1:2.7) fixed combination tablet (Cuarsucam/Winthrop, Sanofi-Aventis, 
Paris), in a three day regimen (141).  
 
 
Figure 2: Chemical structure of amodiaquine. 
 
Piperaquine (PPQ) represents a bisquinoline structure related to chloroquine (CQ) 
synthesized in France for the first time in the 1960s (179). The drug was re-discovered in 
China during the 1970s, having been developed towards a fully operational antimalarial. It 
was subsequently launched as a monotherapy regimen in the South of China during the 1980s 
(84) as a response to the rise of chloroquine resistance. Unfortunately, resistance to PPQ 
readily emerged, forcing its abandonment in 1992. In 2000, PPQ use was resurrected in 
combination with dihydroartemisinin (DHA) for the Vietnamese national malaria control 
program. Its success in SE Asia has prompted the initiative to introduce the DHA-piperaquine 
ACT as a fixed combination in the African continent. PPQ is a very long half-life drug, 
making DHA-PPQ particularly interesting as an ACT, due to an expected long post-treatment 
protection against new infections (39) On the other hand, this long pharmacokinetic tail 
makes it prone for the progressive selection of resistance, as it has been proposed for 
lumefantrine (77). Its mode of action is still not known. 
 
 
Figure 3: chemical structure of piperaquine. 
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1.8.2 The aminoalcoholquinolines – mefloquine and lumefantrine 
Mefloquine (MQ), a drug resulting from the Vietnam War driven research at the Walter Read 
Institute, is a very long half-life antimalarial (12-25 days) (42, 43, 214). Massively launched 
in Thailand during the 1980s as a response to increased CQ and sulfadoxine-pyrimethamine 
(SP) clinical failure, resistance to this drug readily developed. MQ was partially rescued 
during the 1990s through its combination with artesunate, constituting the first formal ACT 
(140). Its long half-life has made this antimalarial attractive for use as a prophylaxis agent for 
non-immune travellers (66). The MQ mode of action is not completely understood, with 
some authors proposing to act as an heme biopolymerisation blocker (as CQ), while others 
providing evidence for an action outside the food vacuole (59, 164).  
 
 
Figure 4: Chemical structure of mefloquine. 
 
Lumefantrine (also called benflumetol), another arylaminoalcohol quinoline (fig. 5) was 
developed by the National Military Academy of Sciences in China during the 1980s (31). 
Lumefantrine is at present exclusively used in combination with artemether (Coartem
®
, 
Novartis, Basel, Switzerland). Artemether-lumefantrine is globally the most implemented 
ACT, being present in the malaria control programs of the majority of the African 
countries (189). Its mode of action is still unknown, although the positive correlations in 
vitro with MQ IC50’s and potential common aspects of the resistance mechanisms (e.g. 
both involving the pfmdr1 gene), suggests a possible overlap of pharmacological targets 
(158).  
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Figure 5: Chemichal structure of lumefantrine (benflumetol). 
 
1.8.3  Quinine and its mode of action: 
Quinine is a natural extract from Quinchina bark with a history of efficacy of more than 350 
years. Discovered in the Northern Peru during the Spanish colonial times by the XVII 
Century, it was imported to Europe.  For 200 years QN was only available in small quantities, 
as a powder, used as an anti-fever medicine for the society elites. In 1834 quinine was 
isolated as the main active principle, which allowed the possibility of its use as a more 
controlled, purified, drug (74). 
 
Figure 6: The chemical structure of Quinine. 
 
Quinine is still obtained from its natural source due to the difficulty to synthetized its 
complex molecule (fig. 6). Quinine constituted the only treatment option for malaria until the 
emergence in the 1930s and 1940s of synthetic derivatives, namely mepacrine, 
pyrimethamine and chloroquine. Quinine is described as a blood schizonticide for all the 
Plasmodium species  with some gametocytocidal activity against P. vivax and P. malariae.  
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1.8.3.1 Pharmacodynamis, and mode of action 
The mechanism of action of quinine have not been fully resolved, albeit it is assumed that at 
least in part is associated with the disturbance of the haemoglobin degradation in the food 
vacuole, in a way similar to the observed with chloroquine (144). As with mefloquine, it has 
also been proposed to be able to inhibit the ingestion of haemoglobin by the parasite (59). 
Quinine has a narrow therapeutic index due to its association with a range of adverse events, 
including auditory loss (“cinchonism”), hypoglycaemia and hypotension, and a broad range 
of directly or indirectly associated clinical symptoms. Due to this, quinine should not be 
applied in any circumstance as a bolus intravenous dose (1, 194). The parasite reduction ratio 
of quinine has been estimated to be 1:250, leading to the necessity of steady state quinine 
levels with a minimum plasma concentration of ca. 6 µg/mL, throughout the 7 day treatment 
course, in order to guarantee therapeutic success. (159) 
1.8.3.2  Pharmacokinetics 
Quinine is a rapidly absorbed when administered orally or intramuscularly, with a peak 
plasma concentration (Cmax) reached in 2-4 hours (Tmax). The drug is characterized by an half-
life of ca. 10-20 hours (100, 159). Quinine is mainly metabolized towards the less active 3-
hydroxyquinoline through the action of hepatic CYP3A4. Approximately 20% of the 
administrated dose is unchanged and eliminated renally. The volume of distribution (Vf) of 
the drug is decreased during acute malaria stages, increasing as the infection is resolved and 
the patient recovers. 
 
1.8.4 Artemisinin derivatives - the central components of ACT 
The active principle of artemisinin is found in a natural herb, Artemisia annua, a plant which 
extracts have been claimed to have antipyretic properties for more than a Millennium in 
mainland China. In 1967 the Chinese government initiated a large survey programme of the 
local botanic resources, searching for natural products with therapeutic potential. Following 
this programme, the works of ancient Chinese tradition medicine were scrutinized, including 
the manuscripts of Ge Hong from 340 AD, where the use of teas based in “quing hao” 
(Artemisia annua, sweet wormwood) were recommended for attenuating fevers. Artemisinin 
(“quighaosu”) (fig. 7), was isolated in 1972 by Chinese researchers as the active antimalarial 
constituent present in the plant (95). 
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Figure 7: Chemical structure of artemisinin. 
 
Artemisinin itself is not presently used in large scale, having been surpassed by semi-
synthetic derivatives, namely the oil soluble artemether and the water-soluble ester 
artesunate. It is to note that one disadvantage of this presently used first generation semi-
synthetic compounds is the absolute requirement of natural artemisinin as starting synthesis 
material (156). 
1.8.4.1 Mode of action and pharmacodynamics 
Artemisinin and its derivatives (ARTs), albeit most effective against the trophozoites forms 
have in general a broader anti-parasitic action as compared with the quinoline based 
antimalarials, significantly affecting most of the P. falciparum intra-erythrocytic cycle stages 
(197). ARTs selectively concentrate in infected RBCs, as compared with uninfected ones 
(75). It is generally accepted that the action of ARTs is dependent on their activation, through 
the collapse of its characteristic intra-molecular peroxide bridge. Conversely, there is no 
consensus on the central event of ARTs anti-parasitic action (80, 92). Several hypotheses 
have been put forward for mechanisms leading to fast and pleiotropic effects in the parasite. 
These can be classified as, (a) through a non-specific action, by generating oxygen radicals 
(38) which further exacerbate the oxidative stress associated with the parasite hemoglobin 
catabolism processes (15, 71, 79) or, (b) through the interaction of the drug with specific key 
molecular targets essential for the survival of the pathogen; these include, to name  few, 
components of the mitochondrial electron transport chain (106), the parasite's SERCA pump 
(PfATP6/PfSERCA)(55), the redox cycling associated flavoenzyme disulfide reductase 
enzymes (81), the  translationally controlled tumor protein (TCTP)(20, 57), or the essential P. 
falciparum exported protein 1 (pfEXP1), a membrane bond glutathione S-transferase (109). It 
is likely that the action of these drugs might actually involve several mechanisms acting 
simultaneously, influenced by specific contexts e.g. the genetic characteristics of the parasite, 
the levels of drug exposure, or the presence of synergistic factors like other antimalarials. 
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Artemisinins are the fastest acting antimalarials in use, with 48 hours based parasite reduction 
ratios (PRRs) of 1:10.000 (see section 1.9). 
1.8.4.2 Pharmacokinetics  
The artemisinin class drugs are rapidly but incompletely absorbed after intramuscular or 
oral administration. Due to differences in absorbance, significant inter-individual peak 
concentration (Cmax) variation is well documented. ARTs undergo significant first pass 
metabolism. This class of drugs are prone to exhibit time dependent pharmacokinetics 
involving a phenomenon of self-induction elimination, especially concerning artemisinin, 
with a significant reduction in its area under the curve (AUC) during the course of 7 doses 
regimens (10). 
Artesunate (ATS) is the most versatile artemisinin derivative in clinical use due to its water 
solubility. This characteristic allows its application beyond the more common oral route, 
including injectable and per-rectum route formulations (44). Artesunate represents an 
emerging alternative to quinine as a rapid treatment agent for situations of severe malaria 
(51, 52, 174). 
Artesunate is extensively metabolized towards the pharmacodynamically active metabolite 
dihydroartemisinin (DHA) by the hepatic cytochrome P450 system, this being further phase 
II conjugated through the action of the UDP-glucuronosyltransferases isoforms 1A9 and 
2B7 (89). ATS has an extremely short half-life of 15-30 minutes, a characteristic that leaves 
the possibility of this being essentially a pro-drug (153), with DHA being the main 
responsible for the antimalarial activity (103, 195). The half-life period of DHA varies 
inter-individually, in a range of ca. 30-120 minutes  (93) In vitro data provide evidence for 
CYP2A6 as the major metabolizing enzyme for artesunate (107).  
The use of artemisinin in monotherapy is associated with a high incidence of recurrent 
infections explaining the need of combination with other antimalarial drugs for a 
sustainable efficacy. 
Due its key importance in the global treatment of malaria, artesunate represents a main 
focus of this thesis.  
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1.9 ARTEMISININ COMBINATION THERAPY (ACT) 
 
The operational concept of ACTs is dependent on the extremely fast pharmacodynamics 
action of its artemisinin derivative partners (ARTs). With a characteristic parasite reduction 
ratio (PRR) of 1/10.000 in the first 48 hours of treatment (215), its action in the combination 
allows a fast reduction in the patient parasite load in the first hours of treatment.  The 
remaining parasites are then eliminated by the long half-life partner drug - typically an 
antimalarial of the quinoline structural class - now left to handle a parasite population 
thousands-fold smaller than at clinical presentation. Seen in function of time, if the slow 
acting long standing drug, with a characteristic PRR of 1:100 (data available for mefloquine), 
would act alone in monotherapy, by the time that would reach the same low levels of 
parasitaemia (if reaching them at all) its own concentration would be significantly lower, as 
compared with the situation aided by ART (fig. 8). It is likely that the remaining parasites 
would then be exposed to sub-therapeutic levels of the drug. This not only would be non-
efficacious to eliminate this parasite population, but would also set the conditions for 
promoting the development of resistance.  
 
Figure 8 – The concept of ACT action herein depicted with the example of artemether-lumefantrine 
(AL). In this representation, lumefantrine is considered as having the same parasite reduction ratio 
(PRR) as mefloquine. The curve is based on published pharmacokinetic data following a standard six 
AL dose regimen (104). Figure adapted from Piedade and Gil (153) 
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The ACT partners are hoped to be associated to different mechanisms of action, promoting 
possible situations of synergy and an expected reduction in probability of resistance 
emergence. In the moment (November 2014), two major ACTs represent the backbone of 
most African national malaria control programs: artemether-lumefantrine (AL) and 
artesunate-amodiaquine (ASAQ). To this adds the pioneering use of artesunate-mefloquine in 
Thailand, which represents the first employed ACT in a national malaria program. Two other 
formulations, representing second generation ACTs, are also emerging: dihydroartemisinin-
piperaquine (224) and artesunate-pyronaridine (25).  
The first generation ACTs have been notoriously successful, being associated with very 
significant decreases in malaria incidence worldwide (218). Such success has prompted the 
reemergence of the national malaria elimination plans in the last years, which include large 
mass ACT administration plans (186). Unfortunately this drug strategy has not proved to be 
totally resistance proof, as signs of in vivo decreased sensitivity to its components - including 
the artemisinin derivatives - are emerging, as first noticed for artesunate-mefloquine, in 
Thailand (29, 157). In this region, ACT came as a response to the fast declining efficacy of 
mefloquine monotherapy, its introduction leading to a remarkable decrease in clinical failure. 
But the parasite kept developing eventually becoming less sensitive even to the combination. 
Although the regimen has been modified and upgraded throughout the years since its 
introduction (29), resistance to the artesunate-mefloquine combination has been recognized 
since the late 1990s (155, 157). Partly this evolution can be considered as a consequence of 
the fact that this ACT was designed in order to increase the useful life span of a failing drug 
(mefloquine), a strategy no longer supported by the WHO.   
In vivo and in vitro resistance to mefloquine has been strongly associated with the presence 
of increased pfmdr1 copy number in the multidrug resistance gene (pfmdr1) (155, 157), a 
frequent occurrence in South East Asia and in some regions of South America, but a 
relatively rare event in the African continent (202). 
Soon after its first implementations in Africa, AL was shown to drive the post-treatment 
selection of the pfmdr1 a.a. 86N-coding allele in clinical efficacy trials performed in Zanzibar 
(182, 184). Soon this observation was confirmed in most settings where AL has been trialed 
(13, 50). Recent studies have further shown that the pfmdr1 86N/184F/1246D haplotype is 
associated with parasite survival at blood drug levels expected to be therapeutically effective 
(116). 
Besides mefloquine and lumefantrine, in vivo resistance to amodiaquine has been observed 
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(86, 142), even in the context of ACT (87). Finally, concerning piperaquine, part of a second 
generation ACT planned to be implemented in Africa, it has been long known that the 
parasite is able to development resistance against these drug, at least when it was employed 
as a monotherapy in Southern China 25 years ago (44).  
In History, P. falciparum parasite has never been submitted to such global and diverse drug 
pressure. It is conceivable that the parasite populations are being stressed to evolve towards 
molecular mechanisms of multidrug resistance, akin to the observed with neoplastic cells. 
The development of such broad range mechanisms of resistance carry the danger expressed in 
the classical concept of multi-drug resistance: that the exposure to one or a limited range of 
drugs will promote the resistance not only against these, but to a spectrum of other 
structurally unrelated ones (73). 
With a reduction of the long-standing partner efficacy, the ART component will be under 
increased pressure as, operationally, the combination will progressive become more like an 
ART monotherapy. This, associated with the referred potential of the parasite to resist to 
diverse quinoline drugs, raises a concern that represents the aim of the present thesis: the 
future of the two critical short half-life antimalarials – the artemisinin derivatives as the 
central components of ACT, and quinine, still the key drug in the treatment of severe malaria. 
 
1.10 P. FALCIPARUM DRUG RESISTANCE  
Drug resistance has been defined to be “the ability of the parasite species to survive and/or 
multiply despite the administration and absorption of a drug given in doses equal to or higher 
than those usually recommended but within the limit of tolerance” (216). What this definition 
implies is that the clinical failure of a treatment should not be immediately considered as a 
situation of resistance by the pathogen. This could actually be due to a lack of sufficient 
exposure because of particular individual pharmacokinetics, situations of drug-drug 
interactions, lack of compliance, etc. But assumed that the exposure is the correct one, the 
development of resistance can be operationally understood as the collapse of the therapeutic 
window of the drug. The progressive necessity of ever increasing blood drug concentration 
because of the decreased sensitivity of the parasite pushes the exposure towards a risk of drug 
associated adverse events. When clinical cost-benefit of applying the drug is not acceptable 
anymore, a situation of full resistance has been reached (fig. 9). 
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Figure 9 – Drug resistance is ultimately defined as the clinical cost-benefit balance between 
increasing the drug doses as a response to the decreased sensitivity of the pathogen, and the drug 
induced toxicity associated with these increased concentrations. 
 
Mechanistically, resistance is associated with the inability of the drug to interact 
appropriately with its pharmacological target. Briefly, this can be achieved by three general 
mechanisms: 
A. A change or alteration of the drug target.  
B. The bio-transformation of the drug, rendering it inactive, an action unusual in the context 
of the limited parasite drug metabolism capacity, including doubts about the existence of 
cytochrome P450s in P. falciparum (152). 
C. Limited access to the target: usually resulting from the action of trans-membrane 
transporters, which once mutated might be able to increase their capacity of efluxing the drug 
from its target compartment, or limit their accumulation by decreasing their active import (97, 
169). 
To note that still other mechanisms, like compensatory mutations increasing the fitness 
capacity of the parasite, can significantly contribute for its survival under drug pressure (166). 
 
The emergence of drug resistance is dependent on the action of a stressor (generally the drug 
itself) upon the natural background noise of natural mutation rates in the parasite genome. 
Many of these rare events correspond to mutations that drive changes in essential proteins 
leading to a putative decrease on their functions. These populations of parasites normally do 
not thrive in the general population, due to the decreased fitness associated with these 
mutation carriers under normal (i.e. drug pressure free) environments (82, 166). But upon a 
sufficiently intense stressor the cost benefit can change, as the decrease in fitness is 
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compensated by a vast superior survival rate under drug exposure (67). This has been 
observed, for example, by the selection of pfmdr1 duplications - a mutation otherwise rare in 
Africa - in Ghana, upon the pilot use of sub-therapeutic levels of mefloquine (123, 200).  
The network of factors involved in the selection of these rare events is complex, including 
pharmacokinetic factors, treatment compliance, levels of immunity (influencing the 
parasitemia burden while allowing thrive of less fit, potentially resistant parasites), among 
others. Anyway, conceptually, drug resistance development strongly relies in repeated events 
of sub-therapeutic drug exposure. It is in this context that the aforementioned 
pharmacokinetic mismatch present in the available ACTs is of concern (61). 
 
1.11 P. FALCIPARUM ARTEMISININ RESISTANCE  
1.11.1 Origins and operational definition 
The present operational concept “artemisinin resistance”, assumed during the works of this 
thesis, is defined by the occurrence of delayed parasite clearance observed after treatment 
with an artesunate monotherapy, or ACTs. Essentially, the present concept of artemisinin 
resistance is essentially only based in the clinical/parasitological response to artesunate 
monotherapies. In brief, the criteria are: recrudescence inside a 28 day post treatment follow 
up, upon a supervised 7 day regiment, with confirmed plasma levels indicating appropriate 
exposure, an initial parasitemia <100.000 parasites/µL, significantly increased parasitaemia 
clearance time, and exclusion of reinfection events. 
Artemisinin resistance was firstly suggested in the beginning of the 2000s upon several 
observations of treatment failures after the newly implemented ACTs (2, 205) (Table1). Due 
to the confounding effect of the presence of the long half-life partner, the performance of 
artesunate monotherapy efficacy trials with exploratory objectives was subsequently 
proposed (135). The first careful study with such a design was performed in the Southern 
Thai-Cambodian border regions (137-139). It effectively showed the presence of a fraction of 
infections with significantly increased clearance times, associated with clinical failure (i.e. 
recrudescence), as well parasites with increased DHA IC50’s. This data has been subsequently 
confirmed with larger studies, albeit with no correlations found with ex vivo DHA IC50 
values (53). This lack of correlation has been justified by the inadequacy of the present in 
vitro methods to evaluate short-term fast acting drugs as artemisinin and its derivatives (5). 
The issue has been recently claimed to have been resolved with a new ring stage in vitro test 
design (222). This method was pivotal in the recent identification of genes polymorphism 
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(K13 propeller) involved in the great Mekong sub region to the parasite resistance to 
artesunate (7, 9, 193). 
Albeit many issues concerning the claims of artemisinin resistance are still to be resolved 
(98) and advise caution (58), the reality is that they are important for at least one reason: 
recent reports have shown that it is likely that the therapeutic index of artemisinin (in this 
specific report, artesunate) is narrower than initially thought. Bethell et al have shown in 
Cambodian subjects that a relatively small increase in the 7 day regimen dose from 4 to 6 
mg/Kg gives rise to an unacceptable risk of neutropenia ((19). 
Table 1: Summary of the status of artemisinin resistance in the Greater Mekong Sub-region 
 WHO global malaria Program, http://www.who.int/malaria/publications/atoz/update-artemisinin-
resistance-jan2014/en/ 
 
 
1.11.2 Markers of resistance 
Due to the global potential importance of the arteminin resistance phenotype, intense research 
has been conducted trying to understand the molecular basis of inter-parasite differences in 
artemisinin response. A number of candidates showing mutations possibly associated with 
such phenotypes have been proposed. These have emerged from different approaches, 
including in vitro or ex vivo gene/phenotype associations, animal models, and in vivo 
analysis of treatment outcomes.  This set comprises a number of genes coding for confirmed 
and putative drug transporters like pfMDR1/Pgh (157) pfCRT (177), pfMRP1 (160) and 
pfMDR6 (209) potential targets as pfATP6 (99) and pfTCTP (20, 56). Some of these 
transporters are described in further detail in the 1.12 section. Also, more general homeostasis 
related enzymes, essentially derived from animal models, have been considered, as PcUBP1 
(ubiquitin C-terminal hydrolase)(88). To this adds the aforementioned K13 propeller gene, 
associated with delayed parasite clearance times in South East Asia (7). 
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1.12 DRUG RESISTANCE ASSOCIATED GENES 
A brief introduction to the main genes associated with antimalarial drug resistance studied in 
the context of the present thesis.is presented.  
1.12.1 Plasmodium falciparum chloroquine resistance transporter (pfcrt) 
This 13 exon gene located in chromosome 7, codes for a 424 a.a., 10 transmembrane 
domain protein localized on the parasite food vacuole membrane (63). It has been described 
to play a key role in P. falciparum resistance to chloroquine. The encoded protein PfCRT is 
proposed to be a member of drug metabolites transporter superfamily (120). The presence 
of single nucleotide mutations (SNPs) in pfcrt can confer to its coded protein the capacity to 
transport the chloroquine out of the digestive vacuole (26, 119, 172). The K76T mutation 
has been identified as the key change in the development of chloroquine resistance (178), 
possibly supported in vivo by a number of other SNPs along the gene open reading frame 
(ORF)(47). The efflux of chloroquine (172) out of the food vacuole is expected to decrease 
its concentration in its lumen (26, 121, 172). Such action is consistent with the development 
of a chloroquine resistant phenotype as the target of chloroquine (CQ), the heme 
biocristalization process following the digestion of hemoglobin, is specifically situated in 
this organelle.  
pfcrt SNPs have also been found to be associated with the in vitro and/or in vivo parasite 
response to LUM (183), MQ (178), quinine (60), artemisinin (33, 34, 178), and possibly 
PPQ (54). Consistent with these observations, recent in vitro data has pointed for the 
capacity of this protein to transport antimalarials besides CQ (16). 
The normal (i.e. physiological) functions of this protein are still not completely understood. 
Recent evidences point for a potential capacity to efflux peptides and glutathione (148).  
1.12.2 Plasmodium falciparum multidrug resistance 1 (pfmdr1) 
The discovery of pfmdr1 was inspired by the homology with the p-glycoptotein (Pgp), a 
human ATP binding cassette transporter associated with multidrug resistance in cancer. 
pfmdr1 represents an intronless gene located at chromosome 5. It codes for the P- 
glycoprotein homologues (Pgh), a protein of 1419 amimoacids, dependent on the extension 
of a central polymorphic asparagine based repeat segment. Pgh is essentially located in the 
food vacuole  FV membrane, with a small fraction present in the plasma membrane (108). 
It is probably oriented towards the lúmen of the vacuole (164). Polymorphisms in pfmdr1, 
including increased copy number and sequence variation (specially N86Y, 1034, 1042 and 
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D1246Y) have been reported to modulate the parasite susceptibility to mefloquine(37, 52, 
112), halofantrine (161, 175, 176) lumefantrine(117, 182, 184), quinine (161), DHA (157), 
artemisinin (161, 203), chloroquine (14), amodiaquine(85, 87) and  piperaquine (204). In 
vitro approches have supported the view that Pgh functions as a drug transporter (171, 173).  
1.12.3 Plasmodium falciparum sodium/hydrogen exchanger (pfnhe1) 
pfnhe1 codes for a putative member of the Na
+
/H
+
 exchanger family of transmembrane 
proteins. It was discovered upon a quantitative trait loci based analysis of the HB3 X Dd2 P. 
falciparum clone cross, previously used for the isolation of pfcrt (211, 212) but now taking 
quinine susceptibility as the phenotype of interest (60). The gene is intronless and situated on 
chromosome 13. It codes for a large 226 KDa transporter (pfNHE1), comprising 12 trans-
membrane domains. The intracellular localization of pfNHE1 is still under discussion (134), 
albeit it is considered that it is primarily located in the plasma membrane (17). A complex 
microsatellite locus named ms4760 has been discovered in the 3’ region of the gene. Its 
diversity is mainly defined by variation in the number repeats in two microsattelites, DNNND 
(denoted block II) and DDNHHDNHNND (block V).  Significantly higher IC50 is observed 
among carriers of the ms4760-1 allele (2 DNNND copies) (60).  
The physiological function of pfNHE1 has been proposed to be associated with the regulation 
of the parasite cytoplasm pH (17). This function is still under discussion (163) as it has been 
challenged under technical basis (134, 187). Also controversial is the association of pfnhe1 
with quinine susceptibility itself. A reasonable number of studies have been performed, both 
concerning culture-adapted parasites (as with M. Ferdig and colleagues seminal report) and 
ex vivo approaches. The results have been contradictory, with some studies supporting a 
positive association while others not (6, 12, 24, 83, 124, 143, 149, 181, 206).  
The full quinine resistance phenotype is likely to be multi-genic, at least involving also the 
aformentioned pfmdr1 and pfcrt genes, as well as others (e.g. pfmrp1, see section below), and 
the recently unveiled MAL7P1.9, coding for an HECT ubiquitin-protein ligase (170).  
The mechanisms specifically associated with the contribution of the pfnhe1 ms4760 alleles is 
unclear, albeit it has been proposed that the action of quinine could be modulated by changes 
in the parasite intracellular pH. Such changes could result from alterations in the capacity of 
transporting H
+
 by pfNHE1, resulting from different conformations driven by the DNND and 
DDNHHDNHNND polymorphisms (17). Evidently, the validity of this hypothesis is strictly 
dependent on the aforementioned debate on the importance of pfNHE1 as a player in parasite 
pH homeostasis.  
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1.12.4 Plasmodium falciparum multidrug resistance associated protein 
(pfmrp1) 
The pfmrp1 gene codes for a large 12 transmembrane domain ABC-transporter, PfMRP1,  
located in the parasite plasma membrane (70, 96). It has been proposed to act as a 
GSH/GSSG pump (22) involved in the REDOX stress management of the parasite. It is also 
expected to be able to transport a large range of drugs. These functional assumptions are 
supported by studies based on the targeted disruption of pfmrp1 in the W2 clone (160). The 
resulting genetically modified parasites showed not only an accumulation of oxidized 
glutathione (GSSG), but also an increase in the sensitivity to a number of drugs, including 
chloroquine, quinine, piperaquine and – most importantly - artemisinin. This effect was 
shown for some of the tested antimalarials (chloroquine and quinine) as the result of a 
decreased accumulation in the parasite, indicating an efflux activity of pfMRP1. 
pfmrp1 SNPs have been linked with the in vivo parasite response to ACT. This was 
concluded from the observation of significant selection patterns of the I876V a.a. position 
upon artemether-lumefantrine treatment (41) and K1466R with sulfadoxine-Pyrimethamine 
(41). In vitro based reports, including the one part of the present thesis (203)(see results 
section), have also provided evidence for the potential importance of pfmrp1 SNPs in 
modulating P. falciparum drug sensitivity, namely the I876V and H191Y (128, 151) with 
chloroquine, as well as F1390I (128, 151) with quinine. 
1.12.5 Plasmodium falciparum K13 propeller gene 
This gene has been described in P.faciparum in homology to the human KEAP1 gene. The 
726 amino acids protein contains an N terminal containing a plasmodium specific sequence, 
followed by a BTB/POZ domain, and finally by the kelch propeller domain towards the C 
terminal. The K13 propeller has been so far studied in Plasmodium falciparum in in vitro 
adapted parasites that underwent several years of exposure to increasing doses of artemisinin. 
Throughout the process, the exposed parasites gradually accumulated a number of SNPs into 
the C terminal Kelch propeller domain. Some of these SNPs have showed to be correlated 
with the rate of survival rings after the RSA (Ring Stage Survival Assay) (7). This association 
was confirmed in a number of field isolates from Cambodia (fig.10). Finally, these mutations 
were also observed to be associated with Day 3 positivity upon ACT treatment. As a result, a 
set of K13 propeller domain mutations has been proposed in Cambodian plasmodium isolates 
to be associated to the in vitro and in vivo resistance to ART Four main alleles where 
observed as significantly involved: C580Y, R539T, I543T, and Y493H. 
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Figure 10:  Survival rates of Cambodian parasites isolates in the RSA0-3h, stratified by K 13 propeller 
allele. Reproduced from Nature  505, 50–55 (02 January 2014), with the permission from the publisher 
 
Importantly, the gene seems to be able to accommodate significant polymorphism, with 17 
non-synonymous SNPs, having been found in Cambodia (7), showing that probably there is 
considerable room for structural changes in this protein. As in many Kelch proteins, 
mutations in the kelch domain are predicted to alter the protein structure or modify the charge 
altering in the same way the protein biological function. Such changes could eventually allow 
the emergence of a protein better suited to deal with the specific stresses associated with ART 
exposure. 
 
 
Fugure 11: tridimensional representation of the Kelch protein K13 propeller of plasmodium 
falciparum with the mutations position represented in orange dots. Reproduced from Plowe et al, 
Nature 505, 30-31 (02 January 2014), with permission from the publisher. 
 
It became as such important to better understand the origin and distribution of this 
biodiversity in several different settings. ACT treatment efficacy studies were assessed in 
different settings in Africa, India and South-East Asia. The K13 propeller mutations appeared 
to be significantly associated to a mean increase in parasites half-life in South-East Asia, but 
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not in Africa and India. In both India and Africa, the K13 propeller SNPs, when present, were 
different from the one previously described as artemisinin resistance potential markers (9). 
Further investigations aimed to find a common genetic origin to this polymorphism (mutants 
K13 propeller) has showed different strains background for the South African parasites and 
the Asian ones which also has emerged and spread independently throughout South-East Asia 
(193). 
The function of the encoded protein (fig.11) is still under speculation.  Its human homolog 
KEAP1 has been described in lung cancer cells as interacting with the Nrf2 by sequestration 
of this protein in the cytosol. Under oxidative stress, Nfr2 is liberated from the complex 
Nfr2/KEAP1 and induces a cytoprotective response (147). These models have been 
extrapolated to the P.falciparum K13 propeller for whom antioxidant response is high in late 
trophozoite stages, where the hemoglobin digestion is considerable (23) The propeller could 
serve the KEAP1 functions in the parasite, albeit no P. falciparum Nrf2 homologue has been 
identified yet. 
  
1.13 DRUG RESISTANCE ASSESSMENT TOOLS 
Malaria parasite resistance is assessed by several different methods. This being a complex 
phenotype, the several methods are expected to complement each other and being consistent 
with the expected phenotype. The four main approaches are briefly presented here i.e. in vivo, 
ex vivo, in vitro and subsequent molecular methods (57)  
1.13.1 Resistance assessment in vivo 
This is usually based on drug efficacy clinical trials with patient being followed up for a 
specific period after the therapy, typically with end points at post-treatment initiation days 28 
to 52, depending on the drug under study. During the follow up, patients are checked for new 
infections and according to the time to recurrence during the follow up the resistance can be 
classified as RI (parasiteamia after day 14), RII (parasiteamia before day 14) or RIII 
(persistent microscopy detectable parasiteamia from day 0 infections) (150, 210, 219).  Due 
to the difficulty of applying such classification in high transmission settings, the WHO 
developed in 1996 a modified protocol based on the clinical outcome targeted at a practical 
assessment of therapeutic response in areas with intense transmission (216). Therapeutic 
response is presently graded according to an outcome criteria as: (a) Adequate clinical and 
Parasitological Response (RCPA), (b) Early Treatment Failure = ETF, (c) Late 
Parasitological Failure = LPF, and (d) Late Clinical failure = LCF. All this data are validated 
only when the efficacy is adjusted by a molecular tool expected to distinguish recrudescent 
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parasites from new reinfecting ones (185). This method used alone has limitations when the 
drug differential pharmacokinetic in individual, the compliance to the treatment and 
multiplicity of infection are considered (118). As such, to this information on individual 
plasma or whole blood drug levels should be added. These observations can be further 
complemented with ex vivo tests (see below). 
1.13.2 Ex vivo / in vitro assessment of drug resistance 
These have been developed on the basis of a micro-test (drug test in limited volume multi-
well plates) either on parasitized blood samples directly collected from the patient (ex vivo) or 
after the adaptation of parasites to long-term culture in the laboratory (in vitro). This allows 
obtaining an objective quantitative level of the parasite sensitivity to the drug of interest, most 
frequently expressed as different levels of inhibitory concentrations (ICs). The most common 
standard values are the IC50 (inhibiting 50% of the initial parasiteamia growth), IC90 and IC99.  
Parasite growth inhibition can be measured by different techniques, the main ones being: 
 (a) The WHO drug sensitivity test, based on the morphological estimation of parasite growth 
by the counting of the number of parasites that were able to progress until the schizont stage, 
after 24 hours of drug exposure. This assay is economical and simple to perform in the field, 
hence frequently used in ex vivo based evaluations. However, it is very laborious and subject 
to individual variability in the interpretation of the microscope readings.  
(b) The DELI (Double sites Enzyme Linked Immunoassay) methods are based on the 
measurement by ELISA of HRP2 (Histidine Rich Protein) (136) or the pLDH (Parasite 
Lactate Dehydrogenase)(91), two proteins that are continuously expressed in growing 
parasites, being as such proxis of its metabolic activity. These two DELI methods are more 
sensitive than the classical WHO method, needing lower parasites densities. However they 
are both more expensive and difficult to set on field condition.  
(c) The isotopic method which is based on the measurement of a [3H]-labeled hypoxanthine 
(46), which is being incorporated in the course of the metabolic activity of the parasite and 
may be measured in a liquid scintillation counter. This method has a high degree of 
reproducibility and allows for the screening of a large number of P. falciparum strains under 
highly controlled conditions. However it needs well-equipped laboratory facilities, involves 
the handling of radioactive material, and requires high parasite densities. It is essentially not 
viable for large scale field work.  
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(d) The Sybr green method based on the measurement of parasite DNA. Sybr green is a DNA 
intercalating dye, the parasites growth measurement being done by quantifying the dye 
incorporation in the nucleic acids, as a measure of cell multiplication (11, 90). This technique 
is easier, faster and has a reduced cost compared to the DELI methods but it is mainly 
applicable to in vitro studies with culture adapted parasites. The presence of human DNA in 
field samples represents a significant confounding factor for the evaluation of the parasite 
growth ex vivo by these methods (208).  
These tests reflect intrinsic antimalarial drug resistance of the parasite. They not only yield 
quantitative results, but also determine the phenotype of the parasite independently of the 
immune and physiopathological conditions of the host. On the other hand, the correlation of 
in vitro response with clinical response in patients, particularly in the definition of in vitro cut 
offs as informative parameters about in vivo responses, is challenging.  
1.13.3 The molecular methods 
Molecular tools of resistance assessment are per nature second generation technologies, as 
they are dependent on the definition of phenotypes and their subsequent association with 
specific parasite genetic characteristics. Due to its characteristics, this approach is useful for 
the downstream analysis of archive material, or clinical material (typically small quantities of 
filter paper-preserved peripheral blood) transported from remote areas (48). Most of these 
methods are based in the PCR amplification capacity. 
Several molecular tools are used to define the parasite genotype, including PCR-RFLP, q-
PCR and direct PCR amplicons sequencing, to name the most commonly used ones. The 
molecular approaches are potentially most relevant in terms of cost, time and ease of 
performance. A large advantage with molecular marker based resistance vigilance, as 
compared with the much more resource consuming drug efficacy clinical trials, is that it is 
possible to scale up the coverage of the surveillance even when the patient population is small 
and time points are scattered (49). Such considerations assume that the tested molecular 
marker is accurate enough to predict the treatment failure by direct correlation to its allele 
status. This represents a significant challenge, as it is difficult to define a biomarker reflecting 
the clinical level of the drug sensitivity in vivo, as many other parameters interacts especially 
human host factors. So far, no molecular marker is presently available with levels of 
specificity and sensitivity compatible with the demands of replacing phenotypic 
determinations of resistance, particularly in the present context of ACT. An appropriately 
informative molecular tool is likely to be complex and multi probe based, including 
molecular factors from both the parasite and the patient (69).   
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1.13.4 The specific case of artemisinin derivatives 
The classical measurements tools above mentioned have been considered as not ideally 
adequate to detect an early sign of tolerance to treatment when using artemisinin derivatives, 
so some methodological modifications have been proposed: 
(1) In vivo Parasite Clearance Estimation (PCE) 
This tool has been developed to estimate Artemisinin efficacy after the emergence of 
resistance to these drugs threatening the survival of the currently used ACTs (137). It is based 
on the estimation of dynamics characteristics of the initial parasiteamia clearance upon in 
vivo artemisinin derivatives exposure.  Microscopical observation during the treatment course 
provides the clearance profile of each patient, with these data being used to generate 
pharmacodynamics metrics, namely the clearance rate and clearance time. These are 
calculated using an online tool of PCE developed by the WWARN. This PCE allows the 
detection of early signs of parasite resistance to ART, for which clear characteristics for 
resistance are yet to be defined (e.g. cut off IC50s for its main drugs, artesunate, artemether 
and DHA). In this approach, a significant change in the clearance characteristics leading to a 
longer clearance is considered to be a sign of emerging resistance to ART. 
This tool is sensitive to population diversity in malaria immunity levels, as well as to several 
modalities of malaria microscopy (smear preparation, staining and reading), which can 
significantly affect the estimated parasite clearance rate.  
(2) In vitro/ex vivo Ring Stage survival Assay RSA
0-3h
 
This approach aims to determine the percentage of viable parasites at 72 hours, following a 
700‐nM, 6‐hour pulse of DHA. Samples suitable for testing are either adapted parasite lines 
(synchronized at the 0‐3 hour post‐invasion ring stage) in the in‐vitro RSA0‐3h or clinical 
parasite isolates (freshly obtained from patients with malaria and P. falciparum mono 
infection, which are per norm naturally synchronized in the ring stage) in the ex‐vivo RSA. 
This tool is used in complement to the described in vivo method and cannot stand by itself as 
autonomously defining the resistance level of a given parasite population. It has been 
proposed as a step in anticipating the research of new molecular markers (7). 
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2 AIM OF THE THESIS 
 
The overall aim of this thesis was focused in the early detection of Plasmodium falciparum 
decreased sensitivity to quinine and artesunate in correlation with the molecular bases of 
resistance. 
Specific aims 
Study I: To determine for the first time the role of pfnhe1 polymorphism in plasmodium 
falciparum sensitivity in vivo based on a quinine efficacy trial in Mali. 
Study II: To search for novel markers, particularly concerning drug transporter genes, of In vitro 
antimalarial susceptibility through the analysis of adapted P. falciparum isolates from one of the 
global foci of multidrug resistance in SE Asia.  
Study III: To measure the Parasite clearance time in P. falciparum in Mali using the 
microscopy assessment of parasite clearance after a treatment by artesunate in monotherapy  
Study IV: To determine the K13 propeller gene diversity in Mali, searching for correlations with 
the parasite clearance time after ART treatment.  
Study V: To evaluate the use of qPCR as a second generation approach for a more sensitive 
evaluation of parasite clearance, and revisit the potential correlations with the identified K13 
propeller polymorphism in Mali. 
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3 MATERIAL AND METHODS 
3.1 STUDY SITES AND CLINICAL TRIALS  
The clinical studies included in this thesis were all conducted in Mali, West Africa. The trials 
concerned four rural malaria endemic areas, Faladje, Kolle, Bougoula-hameau and Bandiagara 
(fig. 12) The studies took place from 2005 to 2007 for study I, in the period 2010-2011 for Study 
III and V. Concerning study IV, this represented two sets of retrospective samples collected in 
1999-2002, 2003-2005 and one concerning the 2010-2011 period, obtained in frame of the present 
thesis.  
 
 
Figure 12: Study sites localization on the Mali map 
 Published with the kind autorisation of Professeur A.Djimde, (WANECAM)Malaria Reserch and Training Center, 
USTTB, Mali. 
 
3.1.1 Faladje and Kolle 
These are two rural villages at, respectively, 80 km northwest and 57 km southern of the capital 
city of Bamako, Mali. Malaria endemicity in both locations is seasonal mainly occurring between 
July and December in both areas. With maximum rainfalls in August and September, the climate 
is predominantly soudanian (213). P. falciparum infection represents the majority of clinical 
malaria cases (94, 196) 
A longitudinal clinical study of quinine efficacy was conducted in Kolle and Faladje during the 
period between 2005 and 2007. Children presenting with severe case of P.falciparum malaria 
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were included for a 28 days follow-up and treated with intravenous quinine administered in 10% 
hypertonic glucose solution at 12.5mg/kg QN twice daily for 5 days. In 2008, the regimen was 
changed to 8 mg/kg 3 times daily for 7 days with a loading dose of 12.5mg/kg the first day. 
3.1.2 Bougoula-Hameau 
A prospective artesunate monotherapy efficacy study was conducted in Bougoula-Hameau, a peri-
urban village where malaria is holoendemic. Situated in southern Mali (350 km from Bamako), 
climatically it represents a sudanian type zone with a landscape dominated by savanna woodland, 
with tall grass dotted with trees. The climate is under the influence of the humid forest zone with 
an annual rainy period extending for six months or more (from May to October or November) 
(213) The trial was performed at the Bougoula-hameau health center (fig. 13) from December 
2010 to February 2011 and included 100 children with ages from 1-11 years old presenting 
clinically confirmed uncomplicated P.falciparum malaria. 
Figure 13: Bougoula-hameau health center 
 
As for the data and samples before 2010, these were provided from an artesunate monotherapy 
arm included in a clinical efficacy trial conducted in 2002-2005. For both periods the treatment 
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was a 7 days artesunate at 2 mg/kg per day with a loading dose of 4 mg/kg the first day. 
Participants were followed for 28 days. 
3.1.3 Bandiagara 
Bandiagara is a semi-rural area of approximately 13,000 inhabitants in the north-eastern of Mali at 
about 700 km from Bamako, situated on a rocky plain above the Dogon escarpment. It receives a 
mean annual rainfall of 600 mm, supporting a setting of meso to hyperendemic malaria, with 
highly seasonal transmission (154). In this area 97% of malaria cases are associated with P. 
falciparum infections (35, 114). Samples from uncomplicated malaria patients were collected in 
this location as a crosectional survey from studies conducted in 1999-2003 included in the 
analysis of the novel K13 propeller gene. 
3.1.4 Mae-sot 
The Mae Sot District is situated in the Tak province, Western Thailand, bordering Myanmar 
(Burma). As the south-east province near Cambodia, this region is known to be an epicenter of 
malaria drug resistance emergence (131, 223). P.falciparum malaria represents 40% of the clinical 
cases (217).  Infected erythrocytes were collected from clinical cases between 2002 and 2008 and 
cryopreserved at the Sokhlo Malaria Research Unit. Parasite adaptation was performed from this 
clinical material at the Karolinska Institute, followed by in vitro drug susceptibility analysis (IC50 
determinations). 
 
3.2 SAMPLES AND DATA COLLECTION 
Study I was based on a clinical trial conducted in Kolle and Faladje from 2005 to 2008, the 
purpose was to collect parasite DNA from dried blood spots realized during a 28 days follow up. 
Parasite genotyping could thus be realized for pfnhe1 and pfcrt diversities. Clinical and 
parasitological parameters where also collected to assess the in vivo efficacy of QN treatment. 
Study II samples involved culture adapted isolates collected in P.falciparum malaria clinical 
cases in Mae-sot prior to treatment. Adapted parasites were then used to assess the in vitro drug 
susceptibility. 
Study III was involved the performance of thick and thin blood slides in Bougoula-Hameau in 
2010-2011 to microscopy assess the clearance of parasite infections after artesunate 
administration; clinical parameters were also collected for the in vivo efficacy assessment. 
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Retrospective data from a study conducted in the same area by the same team in 2002-2005 for 
artesunate monotherapy efficacy were also considered. 
 Study IV used DNA of parasites collected on blood filter papers prior to antimalarial drug 
administration, during the artesunate monotherapy efficacy study at Bougoula in 2010-2011.  For 
comparative objectives, filter paper preserved blood collected prior to this study in the same area, 
between 2002 and 2005, was also used in this investigation.  Finally, samples cross sectionally 
collected in Bandiagara during a period between 1999 and 2002 were also included.  
Study V used DNA extracted from blood preserved in filter papers obtained from the 
aforementioned artesunate monotherapy efficacy study conducted in Bougoula in 2010-2011. 
DNA was extracted from blood spots representing successive time point samples from the same 
patient after drug administration, and used to measure the parasite clearance using a method based 
on Real Time PCR. 
 
3.3 ETHICAL CONSIDERATION 
Informed consent forms were provided by an indicated field team agent in the local language. 
Inclusion in the trial proceeded upon signed acceptance of its terms and conditions signed by the 
patient or his/her guardian as appropriate. 
Study I was approved by the Ethics Committee of the Faculty of Medicine, Pharmacy, and 
Odonto-Stomatology, University of Bamako (EC number 0522) 
Study II, the collection protocols were approved by the Oxford University Tropical Research 
Ethics Committee (OXTREC 027-04)  
Study III, IV and V were all approved under the same ethical approbation of the Ethics 
Committee of the Faculty of Medicine, Pharmacy, and Odonto-Stomatology, University of 
Bamako (EC number 0520). 
 
3.4 MICROSCOPY 
Conventional microscope based procedures were used for all clinical trial in order to diagnose 
malaria cases, but also as a tool in study III to measure parasite clearance dynamics by sampling 
thin and tick slides every 8 hours. Slides were stained for 20-30 minutes with 5% Giemsa solution 
and were examined under oil immersion (x100 magnification). Parasite density was estimated by 
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counting the number of asexual parasites per 200 leukocytes and multiplying by 40, assuming 
8000 leukocytes/mL (216)  Gametocyte density was calculated by counting the number of sexual 
forms per 1,000 leukocytes and multiplying by eight (207) 
 
3.5 WWARN TOOL FOR PARASITE CLEARANCE ESTIMATION (PCE) 
The World Wide Antimalarial Resistance Network has developed a simple calculator that 
provides measures of parasite clearance from serial parasite count data. The PCE tool has been 
used in our study III to analyze the microscopy counting data according to the protocol published 
on the WWARN website (http://www.wwarn.org/sites/default/files/WWARN-Parasite-Clearance-
Estimator-PCE-Methodology.pdf) 
 
3.6 IN VITRO STUDIES 
The in vitro culture adaptation of P. falciparum was performed for drug susceptibility analysis 
purposes in study II. Reference laboratory clones (3D7, Dd2) were provided by the Malaria 
Research and Reference Reagent Resource Center (MR4, ATCC Massanas Virginia), as well as 
by the Department of Animal and population genetics, University of Edinburgh, UK. 
All parasites were cultured in human O+ RBCs and Malaria Culture Medium made with RPMI 
1640 culture medium supplemented with 10% L-glutamine, 0.05% gentamicine (Gibco
®
 / 
Invitrogen™) and 10% human AB+ serum. Parasites were incubated at 37ºC in air-tight 
environment achieved either by conventional candle-jar technique (199) or involving the use of 
gas (5% O2 and 5% CO2 in N2). Parasites were grown in static manner or in suspension on an 
orbital shaker (50 revolutions per minute), according to the circumstances. Parasite intra-
erythrocytic cell cycle synchronization, when applied, was performed by the incorporation in the 
parasite culture of 5% sorbitol for 10 min (101) or using magnetic columns (MACS
®
, Miltenyi 
Biotec). The later consists in passing the parasites in a magnetic column which will specifically 
retain the mature stages, as they contain the highest amounts of iron molecules trapped in 
homozoine while allowing the rings to be eluted. 
Different antimalarial drugs inhibitory concentrations were determined for the laboratory strains, 
as well as for the fresh isolates, by relative quantification of P. falciparum Histidine-Rich Protein 
2 (pfHRP2) based on a Double-Site Sandwich Enzyme-Linked Immunosorbent Assay (136), 
followed by nonlinear regression analysis (115).  
  33 
 
 
3.7 PHARMACOKINETIC 
For the study I purposes, plasma levels of QN were determined in blood samples collected at 3 
time points: before QN administration on day 0, 7 days after the initiation of treatment, and 14 
days after the initiation of treatment. The protocol was developed and the samples processed at the 
Laboratoire de Pharmacologie Analytique et Pharmacocinétique, Hôpital Saint–Vincent de Paul, 
Paris France. 
3.8 MOLECULAR METHODS 
3.8.1 DNA extraction 
All DNA was extracted from dried blood spots collected on 3MM Whatman (Kent, WA 98032-
1911, USA) filter papers. 
Study I: P. falciparum genomic DNA was extracted from blood blotted onto filter paper samples 
by an established methanol–based method (111). 
Study II: DNA was extracted from frozen isolates originally and adapted clones using the 
ABIPRISM
®
6100 Nucleic Acid PrepStation
®
 (Applied Biosystems™, Fresno, CA, USA) and 
following the manufacturer recommendations.  
Study IV and V: DNA was extracted from dried blood spots using a commercially obtained 
Qiagen DNA blood mini kit (Qiagen, Valencia CA, USA) according to the manufacturer’s 
recommendations. Part of study IV was extracted using the BloodPrep
TM
 Chemistry on a ABI 
PRISM
®
 6100 Nucleic Acid PrepStation
®
 (Applied Biosystems, Fresno, CA, USA) according to 
an established protocol (40).  
3.8.2 Recrudescence/reinfection determination through molecular correction 
For study I we have adjusted the in vivo drug efficacy rate by using two  P. falciparum highly 
polymorphic genes, pfmsp, pfmsp2 and  the  microsatellite Ca1 (129, 185). These biodiversity 
markers were used to distinguish recrudescent parasites from new infections by nested 
polymerase chain reaction (PCR), as described elsewhere (32, 191).  A recurrent infection was 
classified as recrudescence if there was at least one allelic band matching with the corresponding 
baseline sample in all 3 genetic markers, or as a reinfection if there were no matching allelic band 
in at least one genetic marker (118). 
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3.8.3 PCR-Restriction Fragment Length Polymorphism (RFLP)  
PCR-RFLP is a well-established method based on the use of restriction enzymes for SNP 
detection. Restriction enzymes have the capacity to cut DNA at a very specific sequence pattern. 
The presence of a SNP will be detected trough occurrence of restriction or not, leading to different 
patterns of electrophoretic band sizes by the size of restricted fragments. In study I, pfcrt K76T 
SNP was analyzed by PCR-RFLP. 
3.8.4 DNA Sequencing 
Sequencing of DNA was applied in order to identify novel and or consecutive SNPs, as well as 
for a better understanding of microsatellite diversities. This method was thus a better option for 
Study I, part of study II and study IV.  
To measure the pfnhe1 microsatellite ms4760 diversity in Study I, a nested PCR product of 
approximately 350 base pairs were purified as recommended by the manufacturer (USB, 
Cleveland, OH). The amplicons were then sequenced with an ABI 3730XL automatic sequencer 
(Applied Biosystems, Foster City, CA) at the National Institute of Allergies and Infectious 
Diseases (NIAID), National Institutes of Health /NIH), Bethesda, USA. 
In Study II, the Open Reading Frames of the pfmdr1, pfcrt and pfmrp1 genes were fully 
sequenced to determine their genetic variability in laboratory strains in Thai field isolates. 
Amplicons were sequenced through outsourcing (Macrogen Inc., Seoul, Korea).  
For study IV, the K13 propeller ORF SNPs were analyzed by using first obtaining an 859 bp 
PCR product, covering all the known polymorphic regions of this gene. The amplicons were 
subsequently purified on filter plates (Edge Biosystems, Gaithersburg, MD), and 
directly sequenced using an ABI 3730XL automatic sequencer (Applied Biosystems, Foster City, 
CA) (145). 
The analysis of the resulting DNA sequence chromatograms is described in this section under the 
“bioinformatics analysis” section. 
3.8.5 Pyrosequencing 
Developed at the Royal Institute of Technology in Stockholm in 1996 (165), pyrosequencing is a 
method of DNA sequencing based on the "sequencing by synthesis" concept. It relies on the 
detection of pyrophosphate release on nucleotide incorporation, rather than chain termination 
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with dideoxynucleotides (21). This technique is particularly suited for SNP analysis with short 
DNA fragments sequenced directly from PCR amplified products. Also, it is an advantageous 
approach concerning the multiplicity of infection found during clinical trials performed in areas of 
high malaria transmission. As, when appropriately calibrated, this technique allows an estimate of 
the different allele proportions in a single infection (226).  
In study IV, after DNA extraction using the BloodPrep
TM
 Chemistry on ABI PRISM

 6100 
Nucleic Acid PrepStation
®
 (Applied Biosystems, Fresno, CA, USA) the Mal10-688956 and 
Mal13-1718319, SNPs were genotyped by pyrosequencing using a PyroMark ID according to the 
recommendations of the manufacturer (Biotage AB, Uppsala, Sweden).  In study II, this 
technique was also the preferred choice for the determination of the Thai isolates pfmdr1 F1226Y 
and pfmrp1 F1390I polymorphisms. 
3.8.6 Real-time PCR 
Real-time PCR, also called quantitative PCR (qPCR) is a laboratory technique developed from the 
classical PCR through the addition of fluorescent probes able to hybridize and signal the 
accumulation of specific amplicons, allowing estimates of their accumulation, and by inference, 
initial amounts of starting template. It has been proven to be a reference method for accurate 
quantification of nucleic acids amplification since its introduction in the late 1990s. 
In study II of this thesis the method is used to determine pfmdr1 copy number variations in the 
parasite. The protocols were based in the use of specific TaqMan
®
 probes, using an ABIPRISM
®
 
7700 or 7000 Sequence Detection Systems (Applied Biosystems™, Fresno, CA, USA). 
In study V, to assess parasite clearance, both parasite the PgMET (tRNA methionine) and the 
human HumTuBB (part of a human beta tubulin exon 4 gene) loci were quantified in the same 
sample. Sets of primers and double-labelled fluorescent hydrolysis probes specific to PgMET and 
HumTuBB were used to amplify and detect parasite and human DNA in a duplex quantitative 
qPCR, BHQ1 was the quencher used for the two probes. The amplification was performed with a 
thermo LightCycler
®
 480 System (F. Hoffmann-La Roche, Germany). For each time point 
(sample), parasite DNA abundance was normalized against human DNA. A relative parasite 
density was calculated by the delta delta CT method (ΔΔCT) (18, 110). The international standard 
(INT) for P. falciparum DNA (146) which contains white blood cell DNA from the donor, was 
used as a positive control. A cut off of 42 cycles was used to define successful amplifications. 
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3.9 BIOINFORMATIC ANALYSIS 
Basic genomic Information for Plasmodium genes for all studies was retrieved using the online 
databases as PlasmoDB (www.plasmoDB.org) and NCBI Entrez database 
(http://www.ncbi.nlm.nih.gov). In Study I and II, the Sequencher™ software versions 4.6 and 4.7 
(Gene Codes Corporation, Ann Arbor, MI, USA) was used to analyze the sequence output with 
the 3D7 gDNA as reference. Study IV results were analyzed using Sequencher
®
 v.5.0 suit (Gene 
Codes Corporation, Ann Arbor, MI). Genetic variation, namely the presence of SNPs was 
assessed by comparing each sequence to the 3D7 reference (PF13_0238).  
3.10 STATISTICS 
EpiInfo version 6.04 (Centers for Disease Control and Prevention, Atlanta, GA), SPSS 11.0 (The 
Predictive Analytics; IBM, Chicago, IL), and STATA 9.1 (StataCorp, College Station, TX) were 
used to generate summary statistics and to compare therapeutic efficacy in study I. The Spearman 
correlation test was used to assess the relation between ms4760–1 and the pfcrt K76T codon 
mutation. The prevalence of polymorphisms before versus after QN therapy was compared with 
the two-sided Fisher exact test and 2 × 2 contingency table analysis. 
The statistical analysis of association between the Thai isolates genotype and their correspondent 
in vitro drug susceptibility in study II was performed with t-test or Mann-Whitney Rank Sum 
Test when normality of the data failed, and adjusted for Bonferroni significance. Pearson 
correlation was used to check significant positive or negative correlation of the in vitro 
antimalarial drug susceptibility using rational numbers. 
In study III, descriptive statistics were expressed as means, medians, or proportions. Categorical 
variables were compared using two-sided Fisher’s exact test, and continuous variables were 
compared using the Student’s t test or Mann-Whitney test, as appropriate. Multivariable models 
were constructed for the primary and secondary outcomes. All statistical analyses were done with 
Stata version 11.0 (StataCorp. College Station, TX). P values < 0.05 were considered significant. 
Distribution of parasite clearance rate constants and slope half-lives were generated by the new 
WWARN Parasite Clearance Estimator (http://www.wwarn.org/research/parasite-clearance-
estimator) (64) 
Study IV results were analyzed through a parametric T test for the normally distributed variable 
PC99 (time in hours for parasiteamia to be reduced by 99% of its initial value). For the non-
normally distributed parasite clearance slope half-life (time in hours it takes for the parasiteamia 
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to decrease by half) a non-parametric Wilcoxon rank-sum test was used to compare the wild type 
and mutant parasites groups. 
In study V data Cycle Threshold (CT) values were obtained from parasite and from human DNA. 
The ΔCT was obtained by calculating the difference between CT values of the parasite target gene 
(PgMET) and the human reference gene (HumTuBB). The Fisher’s two-sided exact test was used 
when searching for associations between the q-PCR data and the available K13 propeller SNP 
data, determined in the same sample set in a previous work included in this thesis (Ouattara et al.  
accepted). T-test was applied for comparing average PC99 values. 
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4 RESULTS AND DISCUSSIONS 
 
4.1 PAPER I 
Potential contribution of pfnhe1 gene to decreased quinine sensitivity of P.falciparum 
parasite 
Although intra venus administered artesunate was recently shown to be superior and being rolled 
out (180) QN is still the central drug in the management of severe malaria and malaria during 
pregnancy in Africa. Every year thousands of malaria patients rely on its efficacy. But the 
capacity of P. falciparum to resist this drug has long been known (8). In 2004, Quantitative Trait 
Loci (QTL) investigations highlighted the pfnhe1 ORF located microsatellite allele ms4760-1 as 
associated with decreased in vitro response to quinine (60). This information prompted us to 
enquire if the ms4760-1 variant was selected in vivo upon a curative dose of intravenous quinine 
administered in severe case of P.falciparum malaria. For this purpose we have sequenced a pfnhe-
1 ORF region containing the ms4760 microsatellite in parasites collected from infections before 
quinine treatment initiation, and from any case of recurrent parasiteamia during the clinical follow 
up. In parallel, the pfcrt K76T SNP was also analyzed for the same set of sample, to seek for any 
contribution of this gene as reinforcement to the role of pfnhe1 in the response to QN treatment.  
Although the in vivo efficacy of the QN was 100% after molecular correction, we observed a 
selection of the quinine resistance associated ms4760-1 allele by the QN treatment, visible 
through a significant increase in its frequency between the group parasite collected before (D0, 
26.2% of 107) and after the drug administration (46.3% of 54) p=0.01 (fig. 14). In this study the 
pfcrt1 mutation K76T was not selected, although a trend for an increased frequency in the 
subgroup of ms4760-1 carrying recurrent infections was observed. The relatively limited size of 
the study did not allow further conclusions concerning a possible interaction between these two 
genes. 
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Figure 14: Selection of ms4760-1 (ms 1) by quinine but not sulfadoxine-pyrimethamine treatment 
with p=0.01 (1.2–4.8) and p=0.3 (.09–1.4) respectively. 
 
Importantly, the selection of ms4760-1 observed in this study is likely to be specifically associated 
to quinine exposure, as no significant selection was observed among the patients receiving SP 
treatment. A further interesting observation is the fact that this selective effect is more 
concentrated in the parasiteamias detected in the bloodstream at day 14. The inability to detect 
residual QN in the plasma at day 14 by the technique used did not allow to make a direct link of 
selection by this drug, but assuming a canonical intra-hepatocyte stage period, these parasites are 
expected to have been released from the liver 6–10 days earlier (76). At that point in time, 
immediately after the end of the 5 days treatment course, an exposure of parasites to low-level QN 
is to be expected. Another explanatory hypothesis is that the parasites that appeared at day 14 
were indeed present at day 0, but at undetectable levels even by nested PCR. In this scenario, QN 
might have cleared the highly susceptible parasites, while parasites with decreased susceptibility 
present at very low levels would have recovered and became detectable at day 14 or beyond.  
The day 7 treatment course has reduced the recurrent rate and has prolonged the patent 
parasiteamia time by 5 days. 
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4.2 PAPER II 
Novel potential molecular markers of in vitro drug resistance located in pfmdr1 and pfmrp1 
genes 
Southeast Asia is a historical epicenter of emerging P. falciparum drug resistance, which makes 
this region a resource for information on the capacities of the parasite to evade antimalarial action. 
The recently observed decrease in parasite artemisinin derivative susceptibility, the ACT key 
component, reinforces this view.  
Changes in putative drug transporters have been extensively linked with decreased parasite 
antimalarial sensitivity. In this context, and aiming to obtain molecular information with interest 
beyond the SE Asian setting, we investigated the association of in vitro phenotypes of drug 
susceptibility (ICs) with the complete genotype of the aforementioned transporter genes, upon 
adaptation to culture of a set of parasites from the Thai-Burma border. Forty six field isolates were 
culture adapted and their pfcrt, pfmdr1 and pfmrp1 ORFs – coding for the three well documented 
drug resistance genes – fully sequenced. This data was then compared with IC values obtained for 
the long half-life partner drugs LUM and MQ, as well (and with particular interest in the context 
of this thesis) to artemisinin and DHA. 
The 43 fully analyzed parasites for the pfcrt, pfmdr1 and pfmrp1 ORFs revealed new SNPs 
(pfmdr1 F1226Y and pfmrp1 F1390I). From the seven SNPs found in pfmdr1, the newly 
identified F1226Y was significantly associated with increased IC values for ART, MQ and LUM. 
The same pattern was observed for the pfmrp1 F1390I, a SNP present in the transmembrane 
domain 11 of the protein, which has been proposed to be part of a substrate pocket in several ABC 
transporters, including PfMDR1 (62). Even though pfmdr1 F1226Y and pfmrp1 F1390I alleles 
haves similar associated drug response profiles, they were not observed to be linked (P>0.05), 
suggesting that the actions of the respective proteins are not coordinated at the sub-cellular level. 
Pfmdr1 CNV was associated with a significant decreased in vitro susceptibility to ART, MQ and 
LUM, as previously documented (155, 157, 158, 176). 
All 46 field isolates carried the same pfcrt haplotype (Dd2-like), not allowing an evaluation of the 
involvement of this gene in the observed responses. By grouping the different pfmrp1 F1390I, 
pfmdr1 F1226Y and pfmdr1 CNV haplotypes present in the Thai field isolates, we observed a 
progressive increase in the IC50 of the tested antimalarial drugs. In particular, we documented that 
the pfmdr1 CNV is associated with an abrupt leap in MQ IC50 values, and showed a less dramatic 
but still significant effect with ART and LUM, confirming previous findings (36, 155, 157, 158, 
176). 
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The molecular mechanisms associated to these mutations are unknown. A preliminarily in silico 
analysis points for the pfMRP1 F1390I as localized within transmembrane 11, a potential 
substrate pocket (45), where it might modulate the interactions between pfMRP1 and the tested 
antimalarials. As for pfmdr1 F1226Y, it is to note that this change was frequently associated with 
the increased copy number of the gene, which suggests a possible enhancement of the effects 
already associated with the pfmdr1 duplications. Further studies are needed for understanding its 
specific contribution for drug response.   
DHA was tested as a proxy of artesunate action, as this drug can be essentially considered in vivo 
as a pro-drug, with the vast majority of the anti-parasitic action being attributed to the active 
metabolite. No significant associations were found between DHA and these markers. There was 
anyway an overall trend for increased IC50’s for the three analyzed SNPs, a tendency that also 
included the successive accumulation of resistance associated alleles in the same parasite. To note 
that at least pfmdr1 duplications have been already associated with decreased sensitivity DHA in 
vitro (157). 
4.3 PAPER III 
Delayed parasite clearance described as the phenotype of P. falciparum resistance to 
artemisinin is not observed in the sub-Saharan African country of Mali 
In 2008 the first report of a potential emergence of artemisinin resistance parasites in South-east 
Asia was published (137). These observations, confirmed by subsequent studies with artesunate in 
monotherapy or in combination, raise the possibility of an eventual spreading of artemisinin 
resistant P.falciparum (7, 9, 53). 
The emergence of artemisinin resistance in the African continent, or its invasion by SE Asian 
resistant parasites is a main concern. Early and continuous monitoring is essential to anticipate 
measures for the management of malaria resistance to artemisinin in Africa. In this scenario, the 
present study was aimed primarily to evaluate the therapeutic efficacy of artesunate in 
monotherapy, 6 years after the introduction of ACTs as the national policy in Mali. Secondly it 
aimed to identify any trends in the parasite clearance dynamics that might herald the emergence of 
a resistance phenotype.  
The clinical trial tested the efficacy of a curative dose of Artesunate in monotherapy, administered 
once daily for 7 days in a group of 100 children with uncomplicated malaria, in Mali. A close 
follow up of the parasite clearance patterns was performed through frequent sampling and 
microscopy, the data being downstream analyzed using the WWARN PCE tool for the estimation 
parasite clearance parameters. The PCR corrected efficacy of the artesunate administered in 
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monotherapy was 100%, with 98.9% of the included patients having cleared 95% of their 
parasites by 24 hours after the treatment initiation, similar to the result observed 8 years earlier in 
the same area (98.3%). The median parasiteamia half-life in our setting was 32 hours. All these 
results were obtained after adjusting for several parameters essentially for the initial parasiteamia, 
age and sex. Compared with a similar trial previously performed in the same region, the in vivo 
efficacy and the proportion of participants clearing parasites by 24 hours after treatment initiation 
remained unchanged from 2002–2004 to 2010–2011.  
The slop half-life mean of 2.07 and the median parasite clearance time (PCT) of 32 hours 
observed in the present work was markedly lower than the 84 hours reported in western Cambodia 
(53). No participants in our study had a positive blood smear at 72 hours as an in vivo predictor of 
treatment failure with ACTs (188). The efficacy observed in this study is probably due to several 
factors:  (a) firstly, because ACTs have been implemented in Mali recently, as compared to the 
Asian regions, theoretically not allowing time for a full development of the phenotype among the 
local parasite populations (b) the fact that artemisinin have been introduced in the African health 
systems only in combination therapy, (c) finally, given the high intensity of P. falciparum malaria 
transmission in Mali, premunition is likely to serve as powerful delay factor to the emergence of 
artemisinin resistance.  
Nevertheless, variation was detected, reflected in a range of clearance times 
Paper IV 
Non-negligible presence of K 13-propeller domain polymorphism in sub Saharan Africa 
P.falciparum  
Resistance to artemisinin and its derivatives is presently assessed by measuring the parasite 
clearance dynamics in malaria patients, upon treatment with artesunate monotherapy. A genetic 
determinant of this phenotype has been proposed to be the polymorphism of the Kelch propeller 
domain of plasmodium falciparum K13 propeller gene. This gene codes for a putative homologue 
of the human kelch protein family.  
The study IV works comes in logical sequence of study III, which prompts the question if 
artemisinin resistance phenotype is already circulating in Africa. In this work we measure the 
prevalence of P. falciparum K13-propeller polymorphisms in present-day artemisinin-sensitive 
parasite collected in Bougoula-Hameau, and in malaria infections that occurred before ACTs 
introduction in Mali in order to detect any impact of the implementation of these therapies on the 
biodiversity of this gene. 
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Samples were collected prior to all antimalarial treatment from Bougoula-Hameau artesunate 
monotherapy study in 2010-2011 but also in 2003-2005, as well as in Bandiagara in 1999-2002. 
The K13 propeller domain was PCR amplified, sequenced and compared with the described ones 
from SE Asia (7). From all the samples analyzed, 26 presented non-synonymous mutations on the 
kelch propeller domain. The remaining infections were designated “wild types” for the domain of 
interest, by considering the 3D7 clone as the source of the reference sequence 
(http://plasmodb.org/). The 3D7-type prevalence was comparable for all study sites, regardless of 
the study period.  
All the new haplotypes found in Bougoula-Hameau in 2011 were different from the sequences 
derived from infections occurring before ACTs were introduced in Mali. Comparing the slope 
half-life of parasites harboring the mutation and the 3D7 types, no difference could be found in 
the slop half-life in the Bougoula-Hameau samples of the artesunate efficacy study in 2010-2011. 
The difference found in the PC99 mean of 20.6 hours for the mutant and 17.9 hours for the 3D7 
types was not statistically significant.  
Finally, SNPs in the Mal10-688956 and Mal13-1718319 genes, previously proposed as 
contributing to the resistance phenotype in SE Asia (192), were not identified in the analyzed 
Malian malaria infections, which harbored only the 3D7-type sequence. 
In our data set none of the SNPs previously described as strongly involved in artemisinin 
resistance were found, which is not totally surprising as no particularly long clearance values were 
initially observed. However, mutations surrounding one of the key mutation or different amino 
acids at the same positions than Asian parasites were detected among parasites from the set 
corresponding to the post-ACT introduction period (2010-2011). This observation suggests a 
putative initial footprint of a process of selection, possibly derived from drug pressure that is 
unveiling previously undetected parasite populations. Assuming the importance of this gene in 
parasite artemisinin derivative response, this emerging variation supports the view that the 
possibility of de novo foci of artemisinin resistance in Africa should not be ignored.  
4.4 PAPER V 
P. falciparum polymorphism at K13-propeller domain and parasite clearance assessed by 
qPCR 
ACT treated malaria in Mali showed to have a mean PCT shorter than observed in Asia. As 
mentioned, this might be related with parasites being more sensitive, while the drug action is 
probably aided by a stronger immune system response due to the development of premunition. 
The detection of differential clearance times in African infection thus needs the use of more 
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sensitive techniques than the microscopy based procedures. This is of importance, as improved 
technology can enable public health systems to early detect trends in toward parasite clearance 
time increase. 
The final work of this thesis had as such the intention of detecting trends of differential in vivo 
clearance by using a more sensitive method. The study relied on the use of quantitative (Real 
time) PCR to detect residual parasiteamia not measurable by microscopy. Study III was hence 
revisited in order to reevaluate the infection’s PCTs. This led to another issue of practical 
importance: with such improved phenotype, could we better define an association between the 
observed K-13 sequence and PCT in the Bougoula-hameau artesunate mono-therapy study? 
Blood sample were collected on filter paper for each participant before treatment at day 0 and 
successively at day 1, day 2 and day 3 following treatment initiation. Extracted parasite DNA was 
analyzed using a recently published relative quantification method (18). Samples were classified 
as fast or slow clearer plus the group that did not clear the parasitaemia by day 3 of treatment 
(“non-clearers”). The results between the two techniques were compared. The role of K13-
propeller polymorphism in the PCT increase with RT-PCR was investigated. 
64 subjects were analyzed, corresponding to the subset where data both microscopy and RT-PCR 
was available. According to RT-PCR, almost half of the participant did not clear their parasite by 
day 3 (46.26%), i.e 72 hours after treatment initiation. The Fast clearers with no parasite 24 hours 
after artesunate were only 14.06% of the analyzed group.  
The PCT was significantly longer by RT-PCT than microscopy, with a mean molecular PC99 
(mPC99) of 67.1 hours vs 18 hours, respectively. Interestingly, none of the fast clearer participant 
was infected with parasite harboring mutation at K13-propeller, a result motivating much needed 
follow up explorations. Otherwise, no further trends of association were observed. 
The potential consequences of the emergence of artemisinin resistance in the continent are such 
that early surveillance is fundamental and urgent. While in our previous work, resourced by the 
conventional microscopy based approach, no parasites were found after day 2, in the present one, 
P. falciparum DNA was detected by day3 in near half of the analysed patients. Using a recently 
developed Q-PCT method to measure parasite clearance has showed that molecular methods can 
offer the possibility to increase detection sensitivity. This is important because albeit several 
genes have been pointed to be possibly involved in the parasite response to artemisinins, the fact 
is that no molecular marker is available with the potential of being a fully useful molecular tool of 
early surveillance for this phenomenon. Accordingly, for the moment it is clear that the 
development of more precise and complete phenotypes is a valuable alternative. Better 
  45 
phenotypes also lead naturally to an improved background for the definition of future molecular 
markers of resistance through more robust genotype/phenotype associative approaches. This was 
the approach that we also piloted in this work, where the reported trend of absence of K13 
propeller mutants among the fast clearers was only possible to be detected through the more 
sensitive q-PCT phenotyping method.  
This supports the aforementioned view that while genetic markers are not available, such methods 
can be of use for the early detection of delayed clearance phenotype, while setting the phenotypes 
needed for the development of future, better field adapted molecular genetics tools.  
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5 PERSONNAL VIEWS AND PERSPECTIVES 
 
This thesis was essentially articulated around the two most important drugs in the 
management of malaria cases in the daily practice in Africa, artesunate and quinine. 
Artesunate constitute one of the backbones of ACT for uncomplicated P.falciparum malaria 
management, being also increasingly recommended for the treatment of severe cases. As for 
quinine, in practice it remains the main compound for this purpose in the African setting, due 
to its wide availability and affordability. 
Our results hereby show albeit a good clinical efficacy of the quinine in the initial phase of 
management of severe malaria cases was reported, a considerable recurrent rate of 30% also 
occurred inside the 28 day follow up. A non-negligible number of these recurrence happened 
only two weeks after a severe attack, which constitutes an issue of concern that clearly 
justifies the increase in the treatment duration from five days to seven days.  
The observed selection of the ms4760-1 microsatellite allele of the gene pfnhe1 by the QN 
treatment is the first robust evidence of the potential role of this polymorphism in the parasite 
sensitivity to QN in vivo. Unfortunately, our present results, albeit interesting, are not enough 
to make a direct correlation between the presence of ms4760-1 and the resistance to QN, as 
the allele has no predictive values regarding the occurrence of recurrent parasiteamia. In 
short, it seems that ms4760-1 is not central enough in the phenomenon of quinine resistance 
to be by itself sufficiently informative to constitute a valuable (i.e. clinically translatable) 
molecular marker of resistance. Resistance against quinine seems to be a particularly complex 
phenomenon, most likely involving an array of genetic markers, of which pfnhe1 is only one 
of the actors. Accordingly, the observed selection process needs more investigation on 
additional genetic differences between the ms4760-1 alleles reported before the treatment 
which are cleared by the treatment, from the ms4760-1 carriers selected by the presence of 
the QN in low concentration. Another point concerns the initial pharmacodynamics of the 
parasite elimination - the assessment of the clearance during the first 72 hours may give 
different clearance profiles according to the parasite genotype. 
As for artesunate, the clinical efficacy in our studies was good; in our Malian setting no cases 
of significantly prolonged parasite clearance could be observed after a curative regiment of 
artesunate in monotherapy, the reinfection rate being less than 5% for 28 days of follow-up. 
The lack of clinically relevant parasite clearance time increases renders the K13-propeller 
polymorphism unveiled in Mali as such not associated with such phenotypes. On the other 
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hand, one can preliminarily assume that the absence of marked increases in clearance times 
can be justified by the non-detection of the reported Asian resistance associated alleles.  
These studies have been motivated by the documented appearance in Asia of clinical failures 
to the quinine as well as to ACTs. The differences observed in the parasite response to these 
two drugs between the two different setting, South-East Asia and Africa, are probably due in 
part to the history of significantly larger antimalarial availability in SE Asia as compared to 
Africa. Also, due to the characteristics of low transmission of the SE-Asian settings, the 
development of premunition is not as prevalent in the human populations as compared with 
the African context. This creates a situation where almost every infected individual will have 
clinical signs, as it is near naïve to the pathogen, which invariably leads to treatment. i.e. most 
parasite populations are under continuous drug pressure (the selective stressor). Additionally, 
the lack of premunition also means that the patient immunity is not strong enough to deal 
with potential residual (and potentially resistant) parasiteamia resulting from this selection 
process where small difference between sensitivity to the treatment differentiate several 
parasite populations. A probable reflection of this phenomenon has been previously reported 
as the intra-patient selection of pfmdr1 duplication-carrying parasites upon mefloquine based 
regimens (201).  
Presently, Africa is still very different from Thailand. But it is to note that with the 
undeniable success of ACT comes a secondary effect: the decrease in transmission will mean 
that premunition will be less and less prevalent among the children born in this ACT era. And 
with the desired availability and ready access to ACT, the drug pressure over the parasite 
populations is increasing. In colloquial words, we are transforming Africa in a SE Asian type 
of setting. The difference is that in SE Asia, ACT was used to save a failing drug, 
mefloquine, while in Africa the long half-life partners (amodiaquine and lumefantrine) are 
still highly effective. But this might be changing (117).  
And finally the genetic background and geographic origin of the parasite has a big impact on 
the drug resistance emergence. Differences between the SE Asian and African parasite 
populations are likely to be significant. As an example of this view, in our works the novel 
pfmdr1 and pfmrp1 mutations associated with resistance that we found upon the analysis of 
the set of Thai parasites were not found in any of African samples that we ever tested. These 
mutations seem to be absent in Africa. Additionally, SE Asian parasites have been proposed 
to be genomically less stable than the ones found in the African continent, which would 
explain that for example that chloroquine resistance never emerged in Africa, and that the 
prevalence of pfmdr1 duplications is still very low.  
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In conclusion, I personally believe that quinine and artesunate, as long as they are used as 
recommended will still have good longevity in the Malian endemic malaria regions, which 
can be considered as representative of this overall Western Africa region. This is supported 
by a clinical efficacy above expectations (100%). However a close and frequent monitoring 
of their efficacy is vital, as the malaria settings in these regions are changing. And with the 
likely increase in drug pressure one can consider a “last man standing” point of view (122), 
where the remaining parasite populations might be progressively less sensitive to the drugs. 
Both artesunate and quinine are presently “too big to fail”. Hence their useful life have to be 
extended as possible, as in the long term, if history repeats itself and the parasite is up to its 
last achievements, resistance to these drugs will eventually happen. It is more a question of 
“when” (that we can influence) then of “if “(as our influence is probably not strong enough to 
stop the parasite). Understanding the molecular basis of the parasite response to quinine and 
artesunate will help on creating appropriate strategies for protecting these drugs from 
resistance, and with that, gaining time. In my opinion this is of critical importance, as I also 
believe that more antimalarials will be developed and become available in the meantime.  
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